MAPT and Alzheimer disease: Over the past decade, imaging tools like PET-tau and 18FDG-PET have offered a clinically relevant methodology to investigate early pathological biomarkers internal to cells and predict who will convert to AD in addition to cognition (Koychev et al., 2017; Ding et al., 2019).